Med. praxi. 2022;19(1):68-73 | DOI: 10.36290/med.2022.010

How to change cardiovascular prognosis of our patients?

doc. MUDr. Ludmila Brunerová, Ph.D.
Interní klinika FNKV a 3. LF UK Praha

Hypertension and hyperlipidemia as (usually asymptomatic) risk factors contribute to the progression of cardiovascular diseases since younger adulthood (40 years). These patients are exposed to these risk factors for a long time resulting in accumulation of atherosclerotic damage. Early diagnosis and intervention of these factors together with communication with the patient about the risk have the impact on the occurrence of cardiovascular events. We present the case of a 62-year old smoker with acute myocardial infarction and left ventricle dysfunction who has been refusing the pharmacotherapy of hyperlipidemia and hypertension for 20 years.

Keywords: hypertension, hyperlipidemia, early vascular aging concept, cardiovascular risk, vascular age, quality of life, communication with patients, fix drug combinations.

Published: February 23, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brunerová L. How to change cardiovascular prognosis of our patients? Med. praxi. 2022;19(1):68-73. doi: 10.36290/med.2022.010.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060): 2665-2712. Go to original source... Go to PubMed...
    2. Domanski MJ, Tian X, Wu CO, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020;76(13):1507-1516. Go to original source... Go to PubMed...
    3. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. PMID: 31504418. Go to original source... Go to PubMed...
    4. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006 Mar;47(3):345-351. Go to original source... Go to PubMed...
    5. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J Am Coll Cardiol. 2019;74(13):1728-1731. Go to original source... Go to PubMed...
    6. Cífková R, Býma S, Češka R. Prevence kardiovaskulárních onemocnění v dospělém věku. Návrh společných doporučení českých odborných společností. Hypertenze, bulettin České společnosti pro hypertenzi 2005,8(1):5-15.
    7. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low­‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14):1381-1391.
    8. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid­‑lowering therapy. Arch Intern Med. 2005;165(10):1147-1152. Go to original source... Go to PubMed...
    9. Huffman MD. The Polypill: From Promise to Pragmatism. PLoS Med. 2015;12(8):e1001862. Go to original source... Go to PubMed...
    10. Čilíková K. Čas, klíčový hráč v redukci srdečně‑cévního rizika. Medical Tribune 25/2019. dostupné na: https://www.tribune.cz/clanek/45198-cas­‑klicovy­‑hrac­‑v-redukci­‑srdecne­‑cevniho­‑rizika (navštíveno 15. 10. 2021).
    11. ÚZIS. Zdravotnická ročenka České republiky 2018. dostupné na: https://www.uzis.cz/index.php?pg=record & id=8280.
    12. Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018;379(7):633-644. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.